Medford, Mass.-based startup Sofregen Medical Inc. has picked up $8 million in a series B round led by Anzu Partners LLC. The money is earmarked for continued development of Sofregen’s silk protein-based technology and for commercialization of its U.S. FDA-cleared Silk Voice for people with vocal cord problems.
BEIJING – Infection diagnostics specialist Genskey Technologies Co. Ltd., of Beijing, closed a series B financing round to secure ¥100 million (US$14 million) to advance pathogen testing using next generation sequencing. The series B round was joined by SB China Capital, Shanghai Lin Chong Investment Management, and Juyuan Capital.
Paris-based Tissium was first founded in 2013 by professors Robert Langer of MIT and Jeffrey Karp of Brigham and Women’s Hospital as Gecko Biomedical. But now it aims to expand beyond its original focus on surgical sealants and adhesives into barriers, plugs, drug delivery and 3D printed implantable devices. To support that wider focus, the company changed its name and has now raised €38.75 million (US$42.78 million) in a series B financing.
HONG KONG – U.S.-based biotech firm Egenesis Inc., headquartered in Cambridge, Mass., has received $100 million through a series B funding round for the development of safe and effective human-compatible organs through gene editing.
Cytovale Inc., a San Francisco-based medical technology company, has picked up $15 million in financing to advance its technology that enables the early detection of sepsis in the emergency department. Specifically, the company raised $7.4 million in an extension of series B equity financing, co-led by existing investors Breakout Ventures and Blackhorn Ventures. Western Technology Investment also participated, providing a venture debt facility to the company.
St. Louis-based Pieriandx, a clinical genomics informatics company, reported that it has closed a $27 million series B funding round led by Atw Partners and Sjf Ventures. Pieriandx provides a software-as-a-service platform that the company says permits the practice of clinical genomics as a standard of care.
HONG KONG – South Korean pharmaceutical company Chong Kun Dang Holdings recently invested KRW5 billion (US$4.1 million) in Biorchestra Co. Ltd., a Korean startup based in Daejeon that aims to develop Alzheimer’s dementia treatment based on microRNA.
Radiation reduction during imaging procedures is a top priority for hospitals and health care providers. Startup Controlrad Inc. has raised a $15 million series B round to market its Trace mobile C-arm radiation reduction technology for use during fluoroscopically guided procedures. That has already been FDA cleared.
HONG KONG – GI Innovation Inc., a microbiome combination drug developer based in Seoul, South Korea, has recently issued fully paid convertible preferred stock (CPS) worth KRW37.5 billion (US$31 million) for a series B investment.
HONG KONG – South Korean biotech venture Spark Biopharma Inc., based in Seoul, has secured KRW25 billion (US$21 million) in series B funding to support new R&D efforts. The company plans to accelerate its development of small-molecule compound-based immuno-oncology therapeutics and treatments for nonalcoholic fatty liver disease (NAFLD).
RSS
